With a market capitalization (market cap) of $1.55B — a measure of how much the company is worth — Tyra Biosciences, Inc. is the 2284th most valuable company in Healthcare as of August 18, 2026. Shares trade at $26.04, down +0.69% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Visit websiteAs of August 18, 2026, Tyra Biosciences, Inc. (TYRA) is worth $1.55B — this is its market capitalization, the total value of all its outstanding shares.
Tyra Biosciences, Inc.’s market cap is $1.55B, which ranks it #2284 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Tyra Biosciences, Inc. (TYRA) shares trade at $26.04, down 0.69% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025